Co Diagnostics Valuation
| CODX Stock | USD 0.94 0.01 1.08% |
Today, the firm appears to be undervalued. Co Diagnostics owns a latest Real Value of $1.19 per share. The recent price of the firm is $0.94. Our model approximates the value of Co Diagnostics from analyzing the firm fundamentals such as Shares Owned By Insiders of 6.30 %, return on asset of -0.28, and Shares Owned By Institutions of 13.95 % as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Co Diagnostics' valuation include:
Price Book 0.4687 | Enterprise Value -5.4 M | Enterprise Value Ebitda 0.5218 | Price Sales 4.0836 | Forward PE 16 |
Undervalued
Today
Please note that Co Diagnostics' price fluctuation is dangerous at this time. Calculation of the real value of Co Diagnostics is based on 3 months time horizon. Increasing Co Diagnostics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Co Diagnostics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of CODX Stock. However, Co Diagnostics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.94 | Real 1.19 | Target 2.0 | Hype 0.93 |
The intrinsic value of Co Diagnostics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Co Diagnostics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Co Diagnostics helps investors to forecast how CODX stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Co Diagnostics more accurately as focusing exclusively on Co Diagnostics' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Co Diagnostics' intrinsic value based on its ongoing forecasts of Co Diagnostics' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Co Diagnostics' closest peers.
Co Diagnostics Cash |
|
CODX Valuation Trend
Analysing the historical paterns of Co Diagnostics' enterprise value and its market capitalization is a good way to estimate and gauge the value of Co Diagnostics over time and is usually enough for investors to make rational market timing decisions.
Co Diagnostics Total Value Analysis
Co Diagnostics is currently forecasted to have valuation of (5.4 M) with market capitalization of 29.9 M, debt of 2.99 M, and cash on hands of 86.49 M. The negative valuation of Co Diagnostics may imply that the market is not capable to price the future growth of the company or it is pricing it at zero value. It may also suggest that takeover valuation may not have captured all of the outstanding financial obligations of the company both on and off balance sheet. Investors should vigilantly validate all of the Co Diagnostics fundamentals.| Takeover Price | Market Cap | Debt Obligations | Cash |
(5.4 M) | 29.9 M | 2.99 M | 86.49 M |
Co Diagnostics Investor Information
About 14.0% of the company shares are held by institutions such as insurance companies. The company has price-to-book (P/B) ratio of 0.47. Some equities with similar Price to Book (P/B) outperform the market in the long run. Co Diagnostics recorded a loss per share of 1.38. The entity had not issued any dividends in recent years. Based on the key indicators related to Co Diagnostics' liquidity, profitability, solvency, and operating efficiency, Co Diagnostics is not in a good financial situation at this time. It has a very high probability of going through financial hardship in December.Co Diagnostics Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Co Diagnostics has an asset utilization ratio of 7.15 percent. This suggests that the Company is making $0.0715 for each dollar of assets. An increasing asset utilization means that Co Diagnostics is more efficient with each dollar of assets it utilizes for everyday operations.Co Diagnostics Ownership Allocation
Co Diagnostics secures a total of 31.93 Million outstanding shares. Co Diagnostics owns 6.3 % of its outstanding shares held by insiders and 13.95 % owned by institutions. Please note that no matter how many assets the company retains, if the real value of the firm is less than the current market value, you may not be able to make money on it.Co Diagnostics Profitability Analysis
The company reported the previous year's revenue of 6.81 M. Net Loss for the year was (35.33 M) with profit before overhead, payroll, taxes, and interest of 28.74 M.About Co Diagnostics Valuation
Our relative valuation model uses a comparative analysis of Co Diagnostics. We calculate exposure to Co Diagnostics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Co Diagnostics's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 2.6 M | 2.5 M | |
| Pretax Profit Margin | (5.59) | (5.87) | |
| Operating Profit Margin | (6.27) | (6.58) | |
| Net Loss | (5.19) | (5.45) | |
| Gross Profit Margin | 0.39 | 0.40 |
Co Diagnostics Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 29.3 M | |
| Quarterly Earnings Growth Y O Y | 0.308 | |
| Forward Price Earnings | 16 |
Co Diagnostics Current Valuation Indicators
Valuation refers to the process of determining the present value of Co Diagnostics and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value CODX we look at many different elements of the entity such as CODX's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Co Diagnostics, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Co Diagnostics' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Co Diagnostics' worth.Additional Tools for CODX Stock Analysis
When running Co Diagnostics' price analysis, check to measure Co Diagnostics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Co Diagnostics is operating at the current time. Most of Co Diagnostics' value examination focuses on studying past and present price action to predict the probability of Co Diagnostics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Co Diagnostics' price. Additionally, you may evaluate how the addition of Co Diagnostics to your portfolios can decrease your overall portfolio volatility.